Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

535 Barnhill Drive, Indianapolis, IN 46202

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center, located in Indianapolis, is Indiana’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and one of only 51 in the nation. The comprehensive designation recognizes the center’s excellence in basic, clinical, and population research, outstanding educational activities, and effective community outreach program across the state.

The center’s nearly 250 scientists conduct research in four programs. The goals of those programs range from understanding the molecular changes that cause cancer to developing targeted therapies to prevent and treat cancer.

Home to the cure of testicular cancer, the IU Simon Comprehensive Cancer Center has benefitted countless patients around the globe by altering or defining treatment standards for:

  • breast cancer
  • gastrointestinal cancer, including pancreatic and colon cancers
  • genitourinary cancer, such as testis, bladder and prostate cancers
  • hematologic disorders, including multiple myeloma and leukemia
  • thoracic cancer
  • thymoma and thymic carcinoma
  • tumors associated with neurofibromatosis type 1, primarily in children
  • umbilical stem cell transplantation

Each year, the center offers hundreds of adult and pediatric clinical trials. Because of the reach of the Hoosier Cancer Research Network – the community outreach arm of the center – Hoosiers don’t have to travel to Indianapolis for access to the latest trials. Instead, patients across the state are within 60 miles of a clinical research site. A model for community-academic partnerships, the Hoosier Cancer Research Network offers ease of access to clinical studies for patients in rural parts of the state so they can receive treatments close to home.

The IU Simon Comprehensive Cancer Center also is a member of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities.

Website: www.cancer.iu.edu
Contact: (317) 278-5632; iutrials@iu.edu

Trials at this location:

HCRN-BRE18-334

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Status: Open to Accrual
Read More

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Status: Open to Accrual
Read More

HCRN-GU20-444

Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing

Status: Open to Accrual
Read More

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Status: Open to Accrual
Read More

HCRN-LUN21-497

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Status: Open to Accrual
Read More

HCRN-LUN21-530

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Status: Open to Accrual
Read More

HCRN-LYM22-565

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Status: Open to Accrual
Read More

TBCRC046

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)

Status: Open to Accrual
Read More

HCRN-GU14-188

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

Status: Closed to Accrual
Read More

HCRN-GU17-326

A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination with Nivolumab plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab plus Ipilimumab

Status: Closed to Accrual
Read More

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Status: Closed to Accrual
Read More